top of page

About Us
Headquartered in San Diego, California with operations in the U.S. and China, Connect Biopharma is a global, clinical-stage biopharmaceutical company developing innovative therapies that treat inflammatory diseases with the goal of improving the lives of millions of those affected around the world.
The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) and has demonstrated activity in both atopic dermatitis and asthma.

bottom of page

